Musculoskeletal
pain is a known
consequence of repetitive strain, overuse, and work-related musculoskeletal
disorders. These injuries include a variety of disorders that cause pain in
muscles, bones, joints, or surrounding structures. This pain can be acute or
chronic, diffuse or focal. Low back pain is the most common example of chronic
musculoskeletal pain. Other musculoskeletal pain includes tendonitis and
tendinosis, myalgia, neuropathies, and stress fractures.
Request to Get Free Sample Pages at:
The
pathophysiology of musculoskeletal pain is not completely clear, but
inflammation, fibrosis, tissue degradation, neurotransmitters, and neurosensory
disturbances have been implicated. Some clinical symptoms of musculoskeletal
pain include local symptoms of pain or widespread and persistent pain,
tenderness, peripheral nerve irritation, weakness, and limited motion and
stiffness.
Access Detailed Report Summary:
The drug
candidates in musculoskeletal pain pipeline include, but are not limited to,
NEO 6860, Gefapixant, and Cebranopadol. Neomed, Merck & Co. and Grunenthal
Group are some companies involved in musculoskeletal pain pipeline.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment